
**Claims**

1. Use of a combination comprising dexamethasone ~~a glucocorticoid~~ and a compound of formula I or a pharmaceutically acceptable salt thereof:



I

in the manufacture of a medicament for the treatment of cancer.

2. The use according to claim 1, wherein the pharmaceutically acceptable salt of the compound of formula I is the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate or acetate salt.

~~3. The use according to claim 1 or claim 2, wherein the glucocorticoid is selected from the group consisting of dexamethasone, fluocinolone acetonide and prednisone.~~

~~4. The use according to claim 1 or claim 2, wherein the glucocorticoid is dexamethasone.~~

3~~5~~. The use according to any one of claims 1 to 2~~4~~, wherein the molar ratio of dexamethasone ~~glucocorticoid~~ to compound of formula I or a pharmaceutically acceptable salt thereof in said combination is from 1:500 to 500:1.

4.~~6.~~ The use according to any preceding claim, wherein said cancer is selected from a hematologic cancer and breast cancer.

5~~7~~. The use of according to claim 4~~6~~, wherein said hematologic cancer is selected from multiple myeloma, lymphoma and leukemia; or wherein said breast cancer is a triple negative breast cancer.


6~~8~~. The use according to any preceding claim wherein said cancer is relapsed and/or refractory.

79. The use according to any preceding claim, wherein dexamethasone ~~the glucocorticoid~~ and the compound of formula I or a pharmaceutically acceptable salt thereof are to be administered concurrently, sequentially or separately.

810. The use according to any preceding claim, wherein dexamethasone ~~the glucocorticoid~~ is to be administered at a dosage range of from 0.1 to 1 mg/kg body weight patient.

911. The use according to claim 810, wherein dexamethasone ~~the glucocorticoid~~ is to be administered at a dosage range of from 0.3 to 0.5 mg/kg body weight patient.


102. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a combination comprising dexamethasone ~~a glucocorticoid~~ and a compound of formula I or a pharmaceutically acceptable salt thereof:



I

113. A kit comprising a pharmaceutical composition according to claim ~~6~~10, and optionally, instructions for treating a patient.


124. Use of a compound of formula I or a pharmaceutically acceptable salt thereof:



I,

in the manufacture of a medicament for the treatment of cancer, wherein the compound of formula I or a pharmaceutically acceptable salt thereof is to be administered in combination with dexamethasone.~~a glucocorticoid.~~

1~~3~~5. Use of dexamethasone ~~a glucocorticoid~~ in the manufacture of a medicament for the treatment of cancer, wherein a proteasome inhibitor is to be administered in combination with a compound of formula I or a pharmaceutically acceptable salt thereof:



I.